Scientific assets and revenue streams are becoming discoverable
BioVergence does not simply tokenize assets. It makes them machine-readable, rankable, financeable, and eventually tradeable. That opens scientific value to a broader set of qualified investors, partners, and operators.
What BioVergence can structure
IP portfolios
Rights to inventions, methods, data assets, and scientific processes.
Royalties
Existing or future royalty streams tied to products, licenses, or asset performance.
Milestones
Development, regulatory, validation, and commercial milestone rights.
Datasets
Structured data assets, signal packs, cohort intelligence, and usage-rights objects.
Programs
Diagnostics, peptides, biosimilars, and other structured science programs.
Protocol rights
Community-validated product and protocol opportunities that can be packaged, financed, and commercialized.
Why BioVergence?
We're building a unique, vetted, regulated, and partnered ecosystem:
A growing opportunity:
our first live tokenization pilot, with Griffon Pharmaceutical, is already underway.
A larger market:
structured access to a broader base of qualified investors than a single private placement will reach.
Built on real infrastructure:
We're partnered with an established Swiss office with legal, regulatory, and structuring capability.
A repeatable structure:
a standard path, instead of rebuilding a one-off vehicle for every asset.
A patented tokenization approach:
US11551212, US2023-0230079.
Why BioVergence?
We're building a unique, vetted, regulated, and partnered ecosystem:
A growing opportunity:
our first live tokenization pilot, with Griffon Pharmaceutical, is already underway.
A larger market:
structured access to a broader base of qualified investors than a single private placement will reach.
Built on real infrastructure:
We're partnered with an established Swiss office with legal, regulatory, and structuring capability.
A repeatable structure:
a standard path, instead of rebuilding a one-off vehicle for every asset.
A patented tokenization approach:
US11551212, US2023-0230079.
FAQ
Frequently asked questions
Frequently asked questions
Frequently asked questions
What is your tokenization process?
Where do the scientific assets come from?
Who is BioVergence for?
How do I get started?
From signal to structure
Source signal
Identify unmet demand, overlooked science, and market-relevant datasets through community intelligence and domain-specific sourcing.
Structure assets
Convert opportunities into typed, machine-readable asset objects with rights, evidence, qualification states, and economic logic.
Apply intelligence
Use validators, predictors, and AI models to rank, price, and qualify assets for structuring or launch.
Finance and launch
Use pledges, structured issuances, and selective productization to move science assets toward market.
FAQ
Frequently asked questions
Frequently asked questions
Frequently asked questions
What is your tokenization process?
Where do the scientific assets come from?
Who is BioVergence for?
How do I get started?
Scientific assets and revenue streams are becoming discoverable
BioVergence does not simply tokenize assets. It makes them machine-readable, rankable, financeable, and eventually tradeable. That opens scientific value to a broader set of qualified investors, partners, and operators.
What BioVergence can structure
IP portfolios
Rights to inventions, methods, data assets, and scientific processes.
Royalties
Existing or future royalty streams tied to products, licenses, or asset performance.
Milestones
Development, regulatory, validation, and commercial milestone rights.
Datasets
Structured data assets, signal packs, cohort intelligence, and usage-rights objects.
Programs
Diagnostics, peptides, biosimilars, and other structured science programs.
Protocol rights
Community-validated product and protocol opportunities that can be packaged, financed, and commercialized.
Why BioVergence?
We're building a unique, vetted, regulated, and partnered ecosystem:
A growing opportunity:
our first live tokenization pilot, with Griffon Pharmaceutical, is already underway.
A larger market:
structured access to a broader base of qualified investors than a single private placement will reach.
Built on real infrastructure:
We're partnered with an established Swiss office with legal, regulatory, and structuring capability.
A repeatable structure:
a standard path, instead of rebuilding a one-off vehicle for every asset.
A patented tokenization approach:
US11551212, US2023-0230079.
Why BioVergence?
We're building a unique, vetted, regulated, and partnered ecosystem:
A growing opportunity:
our first live tokenization pilot, with Griffon Pharmaceutical, is already underway.
A larger market:
structured access to a broader base of qualified investors than a single private placement will reach.
Built on real infrastructure:
We're partnered with an established Swiss office with legal, regulatory, and structuring capability.
A repeatable structure:
a standard path, instead of rebuilding a one-off vehicle for every asset.
A patented tokenization approach:
US11551212, US2023-0230079.
FAQ
Frequently asked questions
Frequently asked questions
Frequently asked questions
What is your tokenization process?
Where do the scientific assets come from?
Who is BioVergence for?
How do I get started?
From signal to structure
Source signal
Identify unmet demand, overlooked science, and market-relevant datasets through community intelligence and domain-specific sourcing.
Structure assets
Convert opportunities into typed, machine-readable asset objects with rights, evidence, qualification states, and economic logic.
Apply intelligence
Use validators, predictors, and AI models to rank, price, and qualify assets for structuring or launch.
Finance and launch
Use pledges, structured issuances, and selective productization to move science assets toward market.
FAQ